Companies › TCRx Therapeutics Co.Ltd
2 active drug programs in 5 registered trials: 5 Phase 1; Oncology; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| KXV01 TCR Lentinvivo Injection Lentivirus vector delivering personalized tumor-reactive TCR for engineered T-cell therapy | – | Phase 1 | Advanced Solid Tumors; Advanced Solid Cancer | Dec 2026 |
| KSV01 Injection CD19-targeted CAR-T cell therapy using lentiviral vector | CD19 | Phase 1 | Non-Hodgkin Lymphoma; B-ALL | Dec 2028 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07275853 | KXV01 TCR Lentinvivo Injection | Phase 1 | Advanced Solid Tumors | Oncology | Dec 2026 |
| NCT07196579 | KXV01 TCR Lentinvivo Injection | Phase 1 | Advanced Solid Cancer | Oncology | Dec 2026 |
| NCT07246707 | KSV01 Injection | Phase 1 | B-ALL | Oncology | Oct 2027 |
| NCT07596693 | KXV01 TCR Lentinvivo Injection | Phase 1 | Advanced Solid Tumors | Oncology | Dec 2027 |
| NCT07260812 | KSV01 Injection | Phase 1 | Non-Hodgkin Lymphoma | Oncology | Dec 2028 |
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.